CapsoVision (CV) EBT Margin (2024 - 2026)
CapsoVision (CV) posted EBT Margin of 188.11% for Q4 2025, up 15.98% sequentially from 223.88% in Q3 2025, and down 5404.0% YoY from 3.55% in Q4 2024.
CapsoVision (CV) EBT Margin (2024 - 2026) Analysis & Trends
CapsoVision has reported EBT Margin for 2 years, with the latest figure at 188.11% in Q4 2025.
- Quarterly EBT Margin fell 5404.0% year-over-year to 188.11% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 172.57% (changed N/A YoY) and the FY2025 annual result came in at 186.59%, down 1743.0% from the prior year.
- EBT Margin climbed to 188.11% in Q4 2025 per CV's latest filing, from 223.88% in the prior quarter.
- Over five years, EBT Margin peaked at 134.07% in Q4 2024 and troughed at 223.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 12.10% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 23.74% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 19.48% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 29.86% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 24.27% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 13.09% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 8.91% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 18.32% |
| 10 | CapsoVision | 295.13 Mn | 286.05 Mn | 1.87 Mn | -205.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -205.35% |
| Dec 31, 2025 | -188.11% |
| Sep 30, 2025 | -223.88% |
| Jun 30, 2025 | -139.52% |
| Dec 31, 2024 | -134.07% |
| Sep 30, 2024 | -195.35% |
| Jun 30, 2024 | -185.23% |